OncoMatch/Clinical Trials/NCT05819853
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Is NCT05819853 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Semaglutide Injectable Product (Wegovy and/or Ozempic) for pcos (polycystic ovary syndrome) of bilateral ovaries.
Treatment: Semaglutide Injectable Product (Wegovy and/or Ozempic) — Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
Hemoglobin ≥ 12 mg/dL
Anemia, defined as Hemoglobin < 12 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Anschutz/Children's Hospital Colorado Aurora · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify